Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (“BCBSM”), effective September 1, 2026, to provide the CNSide(®) Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. BCBSM serves approximately 5 million commercial and Medicare Advantage members through Blue Cross Blue Shield of Michigan and Blue Care Network, one of the nation’s largest nonprofit Blue Cross Blue Shield organizations. Combined with previously announced agreements, CNSide has now established contracted reimbursement coverage representing approximately 158 million commercial and Medicare Advantage covered lives, reflecting continued execution of the Company's national reimbursement strategy.

"This agreement with Blue Cross Blue Shield of Michigan represents another important milestone in our commercialization strategy to expand patient access to CNSide," said Marc Hedrick, M.D., President and Chief Executive Officer of Cerenome. "With BCBSM, CNSide now has contracted commercial and Medicare Advantage coverage representing approximately 158 million covered lives, further strengthening our national reimbursement platform and expanding patient access across the U.S."